Atrial fibrillation in the elderly: Management strategies to achieve performance measures

AACN Advanced Critical Care

Volumn 25, Issue 3, 2014, Pages 205-212

  Wung, Shu Fen ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT;

AGED; ATRIAL FIBRILLATION; COMPLICATION; HUMAN; PATIENT EDUCATION; RISK FACTOR; SMOKING CESSATION; THROMBOEMBOLISM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CARDIOVASCULAR AGENTS; HUMANS; PATIENT EDUCATION AS TOPIC; RISK FACTORS; SMOKING CESSATION; THROMBOEMBOLISM;

EID: 84904965829     PISSN: 15597768     EISSN: 15597776     Source Type: Journal    
DOI: 10.1097/NCI.0000000000000027     Document Type: Article

References (66)

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995; 155 (5): 469-473.
2. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009; 104 (11): 1534-1539.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke. 1991; 22 (8): 983-988.
4. Magnani JW, Rienstra M, Lin H, et al. Atrial fibrillation: Current knowledge and future directions in epidemiology and genomics. Circulation. 2011; 124 (18): 1982-1993.
5. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996; 27 (10): 1760-1764.
6. Miyasaka Y, Barnes ME, Bailey KR, et al. Mortality trends in patients diagnosed with first atrial fibrillation: A 21-year community-based study. J Am Coll Cardiol. 2007; 49 (9): 986-992.
7. Appelros P, Nydevik I, Viitanen M. Poor outcome after first-ever stroke: Predictors for death, dependency, and recurrent stroke within the first year. Stroke. 2003; 34 (1): 122-126.
8. Miyasaka Y, Barnes ME, Gersh BJ, et al. Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980 to 2000: Report of a community-based study. Stroke. 2005; 36 (11): 2362-2366.
9. Schwammenthal Y, Bornstein N, Schwammenthal E, et al. Relation of effective anticoagulation in patients with atrial fibrillation to stroke severity and survival (from the National Acute Stroke Israeli Survey [NASIS]). Am J Cardiol. 2010; 105 (3): 411-416.
10. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation. 1998; 98 (10): 946-952.
11. Kalantarian S, Stern TA, Mansour M, Ruskin JN. Cognitive impairment associated with atrial fibrillation: A metaanalysis. Ann Intern Med. 2013; 158 (5 Pt 1): 338-346.
12. McDonald AJ, Pelletier AJ, Ellinor PT, Camargo Jr. C.A. Increasing US emergency department visit rates and subsequent hospital admissions for atrial fibrillation from 1993 to 2004. Ann Emerg Med. 2008; 51 (1): 58-65.
13. Wu EQ, Birnbaum HG, Mareva M, et al. Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin. 2005; 21 (10): 1693-1699.
14. Naccarelli GV, Johnston SS, Dalal M, Lin J, Patel PP. Rates and implications for hospitalization of patients /= 65 years of age with atrial fibrillation/flutter. Am J Cardiol. 2012; 109 (4): 543-549.
15. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006; 114 (2): 119-125.
16. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285 (18): 2370-2375.
17. Amin AN, Jhaveri M, Lin J. Hospital readmissions in US atrial fibrillation patients: Occurrence and costs. Am J Ther. 2013; 20 (2): 143-150.
18. Magnani JW, Hylek EM, Apovian CM. Obesity begets atrial fibrillation: A contemporary summary. Circulation. 2013; 128 (4): 401-405.
19. Frost L, Hune LJ, Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study. Am J Med. 2005; 118 (5): 489-495.
20. Anderson JL, Halperin JL, Albert NM, et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 61 (18): 1935-1944.
21. Curtis AB. Practice implications of the atrial fibrillation guidelines. Am J Cardiol. 2013; 111 (11): 1660-1670.
22. Kirchhof P, Curtis AB, Skanes AC, Gillis AM, Samuel Wann L, John Camm A. Atrial fibrillation guidelines across the Atlantic: A comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society. Eur Heart J. 2013; 34 (20): 1471-1474.
23. Prystowsky EN, Camm J, Lip GY, et al. The impact of new and emerging clinical data on treatment strategies for atrial fibrillation. J Cardiovasc Electrophysiol. 2010; 21 (8): 946-958.
24. American Heart Association. Atrial Fibrillation Fact Sheet. http://www.heart.org/idc/groups/heart-public/@wcm/@private/@hcm/@gwtg/documents/ downloadable/ucm-451183.pdf. Dallas, TX: American Heart Association; 2013: 1-3.
25. Ellrodt AG, Fonarow GC, Schwamm LH, et al. Synthesizing lessons learned from Get With The Guidelines: The value of disease-based registries in improving quality and outcomes. Circulation. 2013; 128 (22): 2447-2460.
26. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery; Camm AJ, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31 (19): 2369-2429.
27. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002; 347 (23): 1825-1833.
28. Nantsupawat T, Nugent K, Phrommintikul A. Atrial fibrillation in the elderly. Drugs Aging. 2013; 30 (8): 593-601.
29. Hanon O, Assayag P, Belmin J, et al. Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people. Arch Cardiovasc Dis. 2013; 106 (5): 303-323.
30. Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010; 362 (15): 1363-1373.
31. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285 (22): 2864-2870.
32. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011; 123 (10): E269-e367.
33. del Conde I, Halperin JL. Ineligibility for anticoagulation in patients with atrial fibrillation. Am J Med. 2013; 126 (2): 105-111.
34. Hart RG, Pearce LA, Aguilar MI. Meta-Analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146 (12): 857-867.
35. Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009; 151 (5): 297-305.
36. Pokorney SD, Sherwood MW, Becker RC. Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation. J Thromb Thrombolysis. 2013; 36 (2): 163-174.
37. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999; 131 (12): 927-934.
38. Kagansky N, Knobler H, Rimon E, Ozer Z, Levy S. Safety of anticoagulation therapy in well-informed older patients. Arch Intern Med. 2004; 164 (18): 2044-2050.
39. Wofford JL, Wells MD, Singh S. Best strategies for patient education about anticoagulation with warfarin: A systematic review. BMC Health Serv Res. 2008; 8: 40.
40. Tang EO, Lai CS, Lee KK, Wong RS, Cheng G, Chan TY. Relationship between patients' warfarin knowledge and anticoagulation control. Ann Pharmacother. 2003; 37 (1): 34-39.
41. Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004; 141 (10): 745-752.
42. van Walraven C, Oake N, Wells PS, Forster AJ. Burden of potentially avoidable anticoagulant-Associated hemorrhagic and thromboembolic events in the elderly. Chest. 2007; 131 (5): 1508-1515.
43. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007; 115 (21): 2689-2696.
44. Aliot E, Breithardt G, Brugada J, et al. An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality. Europace. 2010; 12 (5): 626-633.
45. Hendriks JM, de Wit R, Crijns HJ, et al. Nurse-led care vs. usual care for patients with atrial fibrillation: Results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. Eur Heart J. 2012; 33 (21): 2692-2699.
46. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994; 271 (11): 840-844.
47. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995; 98 (5): 476-484.
48. Heeringa J, Kors JA, Hofman A, van Rooij FJ, Witteman JC. Cigarette smoking and risk of atrial fibrillation: The Rotterdam Study. Am Heart J. 2008; 156 (6): 1163-1169.
49. Chamberlain AM, Agarwal SK, Folsom AR, et al. Smoking and incidence of atrial fibrillation: Results from the Atherosclerosis Risk in Communities (ARIC) study. Heart Rhythm. 2011; 8 (8): 1160-1166.
50. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: An update. J Am Coll Cardiol. 2004; 43 (10): 1731-1737.
51. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997; 96 (7): 2455-2461.
52. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-Analysis. J Am Coll Cardiol. 2005; 45 (11): 1832-1839.
53. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 62 (16): E147-e239.
54. Pei DA, Yan YY, Li L, et al. Mineralocorticoid receptor, CYP11B2 mRNA expression, and atrial matrix remodelling in patients with atrial fibrillation. Acta Cardiol. 2010; 65 (5): 527-533.
55. Struthers AD. Aldosterone: Cardiovascular assault. Am Heart J. 2002; 144 (5) (suppl): S2-S7.
56. Dabrowski R, Szwed H. Antiarrhythmic potential of aldosterone antagonists in atrial fibrillation. Cardiol J. 2012; 19 (3): 223-229.
57. Ito Y, Yamasaki H, Naruse Y, et al. Effect of eplerenone on maintenance of sinus rhythm after catheter ablation in patients with long-standing persistent atrial fibrillation. Am J Cardiol. 2013; 111 (7): 1012-1018.
58. Cleland JG, Coletta AP, Castiello T, Clark AL. Clinical trials update from the European Society of Cardiology Heart Failure meeting 2011: TEHAF, WHICH, CARVIVA, and atrial fibrillation in GISSI-HF and EMPHASIS-HF. Eur J Heart Fail. 2011; 13 (10): 1147-1151.
59. Nasr IA, Bouzamondo A, Hulot JS, Dubourg O, Le Heuzey JY, Lechat P. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: A meta-Analysis. Eur Heart J. 2007; 28 (4): 457-462.
60. Opasich C, De Feo S, Cioffi G, et al. Does atrial fibrillation in elderly patients with chronic heart failure limit the efficacy of carvedilol?. Suggestions from an observational study. Ital Heart J. 2005; 6 (4): 323-327.
61. Savelieva I, Camm J. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Pract Cardiovasc Med. 2008; 5 (1): 30-41.
62. Savelieva I, Kourliouros A, Camm J. Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: Review of evidence and clinical relevance. Naunyn Schmiedebergs Arch Pharmacol. 2010; 381 (3): 1-13.
63. Lardizabal JA, Deedwania PC. Benefits of statin therapy and compliance in high risk cardiovascular patients. Vasc Health Risk Manag. 2010; 6: 843-853.
64. Digby GC, Baranchuk A. Sleep apnea and atrial fibrillation: 2012 update. Curr Cardiol Rev. 2012; 8 (4): 265-272.
65. Ng CY, Liu T, Shehata M, Stevens S, Chugh SS, Wang X. Meta-Analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation. Am J Cardiol. 2011; 108 (1): 47-51.
66. Pang H, Ronderos R, Perez-Riera AR, Femenia F, Baranchuk A. Reverse atrial electrical remodeling: A systematic review. Cardiol J. 2011; 18 (6): 625-631.